C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01)
Patent
CA 2606194
The present invention is directed to methods and kits based, at least in part, on the identification of allele-specific responsiveness or non-responsiveness to glatiramer acetate for the treatment of immune disorders, such as relapsing- remitting multiple sclerosis. The allele-specific responsiveness or non- responsiveness is based on polymorphisms in the following genes, CTSS, MBP, TCRB, CD95, CD86, IL-1R1, CD80, SCYA5, MMP9, MOG, SPPl and IL-12RB2.
La présente invention concerne des procédés et des kits basés, au moins en partie, sur l'identification de la sensibilité ou non sensibilité allèle-spécifique à l'acétate de glatiramère pour le traitement de troubles de l'immunité tels que la sclérose en plaques cyclique. La sensibilité ou non sensibilité allèle-spécifique à l'acétate de glatiramère se base sur des polymorphismes des gènes suivants: CTSS, MBP, TCRB, CD95, CD86, IL-1R1, CD80, SCYA5, MMP9, MOG, SPPl et IL-12RB2.
Avidan Nili
Beckmann Jacques
Ben-Asher Edna
Goldstaub Dan
Grossman Iris
Heenan Blaikie Llp
Rappaport Faculty Of Medicine And Research Institute
Teva Pharmaceutical Industries Ltd.
Yeda Research And Development Company
LandOfFree
Markers associated with the therapeutic efficacy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Markers associated with the therapeutic efficacy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Markers associated with the therapeutic efficacy of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1897818